A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
A Phase 1 Open-Label, Multicenter Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HBM7020 in Healthy Adult Participants and Adults With Seropositive Autoimmune Disease
This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Otsuka Call Center
- 电话号码:844-687-3522
- 邮箱:otsukaprofessionalservices@otsuka-us.com
学习地点
-
-
Queensland
-
Brisbane、Queensland、澳大利亚、4006
- 招聘中
- Q-Pharm Pty Ltd
-
接触:
- Otsuka Call Center
- 电话号码:844-687-8522
- 邮箱:Otsuka-ProfessionalServices@otsuka-us.com
-
首席研究员:
- Wong
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria for Healthy Participants (Part 1)
- Participants who are of non-childbearing potential or are using acceptable contraception.
- Body mass index (BMI) and body weight within an acceptable range.
- Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.
Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 2)
- BMI and body weight within an acceptable range.
- Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.
Key Disease-Specific Inclusion Criteria for Patient Participants (Part 2)
-
Confirmed autoimmune disease with appropriate supporting autoantibody findings.
-
Stable background therapy prior to dosing.
-
Active moderate to severe disease consistent with protocol-defined disease activity criteria for:
- Systemic lupus erythematosus (SLE)
- Systemic sclerosis (SSc)
- Rheumatoid arthritis (RA)
- Sjögren's disease (SjD)
Key Inclusion Criteria for Rescreening Participants (Part 2)
- Meets Part 2 disease-agnostic inclusion criteria.
- Stable background autoimmune therapy prior to dosing.
- Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.
Key Exclusion Criteria for Parts 1 and 2
- Pregnant or breastfeeding participants.
- Recent vaccination within protocol-defined timelines.
- Clinically significant medical history or abnormal physical examination findings.
- Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
- Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
- Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1 and Part 2a Dose Escalation
Healthy participants and participants with seropositive systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or Sjögren's disease (SjD) will receive HBM7020 in sequential dose-escalation cohorts during Part 1 and Part 2a, respectively. |
Liquid formulation, administered through intravenous infusion |
|
实验性的:Part 2b
Eligible patients may receive optional retreatment of HBM7020 in Part 2b |
Liquid formulation, administered through intravenous infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48
大体时间:Up to Week 48
|
Up to Week 48
|
|
Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related Infection
大体时间:Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Dose limiting AE Evaluation During Dose Escalation
大体时间:Up to Day 15
|
Up to Day 15
|
|
Number of Participants With Clinically Significant Changes in Vital Signs
大体时间:Up to Week 24
|
Up to Week 24
|
|
Number of Participants With Clinically Significant Changes in Physical Examination Findings
大体时间:Up to Week 24
|
Up to Week 24
|
|
Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)
大体时间:Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)
大体时间:Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Ferritin
大体时间:Up to Week 20
|
Up to Week 20
|
|
Change From Baseline in Serum Immunoglobulin G (IgG)
大体时间:Up to Week 20
|
Up to Week 20
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Area Under the Concentration-Time Curve From Time Zero to Last Observable Concentration (AUCt) of HBM7020
大体时间:Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of HBM7020
大体时间:Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Maximum Observed Plasma Concentration (Cmax) of HBM7020
大体时间:Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Time to Maximum Observed Plasma Concentration (tmax) of HBM7020
大体时间:Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
|
|
Number of Participants With Anti-Drug Antibodies (ADA) to HBM7020
大体时间:Up to Week 24
|
Up to Week 24
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 365-201-00001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD 共享时间框架
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD 共享访问标准
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.